Cogent Biosciences, Inc. (NASDAQ: COGT) has reported its financial results for the fourth quarter and full year of 2025. The company's recent business highlights include the submission of the Summit NDA for Bezulastinib in patients with nonadvanced systemic mastocytosis (nonadvsm) in December 2025, with the Apex NDA submission for Bezulastinib in patients with advanced systemic mastocytosis (advsm) on track for the first half of 2026.
The company's financial position remains strong, with $901 million in funds, sufficient to support operations into 2028.
In terms of specific metrics, the company announced that six abstracts from the Summit trial of Bezulastinib in patients with nonadvsm have been accepted for presentation at the 2026 AAAAI annual meeting. Additionally, the company's Apex trial evaluating Bezulastinib in patients with advsm reported a rapid and deep clinical benefit, with an objective response rate of 57% per MIWG criteria and 80% per PPR criteria.
In terms of financials, the company completed concurrent public offerings of common stock and convertible senior notes in November 2025, resulting in net proceeds of approximately $546.8 million. This has contributed to the company's strong financial position.
The company also shared progress on its internally developed Kras(on/off) inhibitor, Cgt1263, and announced the submission of investigational new drug (IND) applications for Cgt1815, a novel selective pan-Kras(on) inhibitor, and Cgt1145, a novel selective Jak2 V617F inhibitor.
Finally, the company announced the establishment of active expanded access programs (EAPs) for U.S. patients with GIST or SM who meet disease-specific criteria and could benefit from treatment with Bezulastinib or the combination of Bezulastinib and Sunitinib. The market has reacted to these announcements by moving the company's shares -0.79% to a price of $38.94. For more information, read the company's full 8-K submission here.
